JCR Pharmaceuticals 過去の業績
過去 基準チェック /06
JCR Pharmaceuticals's earnings have been declining at an average annual rate of -0.3%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 9.5% per year.
主要情報
-0.3%
収益成長率
-0.5%
EPS成長率
Pharmaceuticals 業界の成長 | 3.4% |
収益成長率 | 9.5% |
株主資本利益率 | -0.7% |
ネット・マージン | -1.2% |
前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00
Sep 06What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You
Sep 04JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00
Aug 23JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00
Aug 09Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts
Aug 03JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00
Jul 26JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00
Jul 12JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
May 22JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00
Mar 18JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00
Feb 29収支内訳
JCR Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 24 | 35,256 | -437 | 14,058 | 11,234 |
30 Jun 24 | 40,208 | 4,098 | 24,708 | 0 |
31 Mar 24 | 42,871 | 5,507 | 12,485 | 11,234 |
31 Dec 23 | 41,365 | 5,364 | 14,321 | 8,802 |
30 Sep 23 | 43,034 | 8,063 | 13,172 | 8,802 |
30 Jun 23 | 35,545 | 4,014 | 11,921 | 8,802 |
31 Mar 23 | 34,343 | 3,772 | 11,678 | 8,802 |
31 Dec 22 | 37,508 | 5,154 | 13,267 | 7,175 |
30 Sep 22 | 38,280 | 6,235 | 13,252 | 7,175 |
30 Jun 22 | 50,875 | 14,343 | 13,943 | 7,175 |
31 Mar 22 | 51,082 | 14,507 | 13,511 | 7,175 |
31 Dec 21 | 50,931 | 16,549 | 14,071 | 5,360 |
30 Sep 21 | 47,517 | 14,899 | 12,771 | 5,360 |
30 Jun 21 | 34,717 | 7,657 | 10,483 | 5,360 |
31 Mar 21 | 30,085 | 6,892 | 8,624 | 5,360 |
31 Dec 20 | 26,128 | 4,137 | 7,243 | 5,997 |
30 Sep 20 | 24,496 | 2,983 | 6,685 | 5,997 |
30 Jun 20 | 24,807 | 3,076 | 7,396 | 5,997 |
31 Mar 20 | 24,781 | 2,678 | 7,638 | 5,997 |
31 Dec 19 | 25,709 | 3,653 | 8,909 | 4,354 |
30 Sep 19 | 24,121 | 3,260 | 9,000 | 4,354 |
30 Jun 19 | 23,638 | 3,802 | 7,802 | 4,354 |
31 Mar 19 | 23,160 | 3,715 | 7,271 | 4,354 |
31 Dec 18 | 20,874 | 2,454 | 7,177 | 4,211 |
30 Sep 18 | 20,682 | 2,566 | 6,745 | 4,211 |
30 Jun 18 | 20,885 | 2,857 | 6,642 | 4,211 |
31 Mar 18 | 20,594 | 3,070 | 6,470 | 4,211 |
31 Dec 17 | 20,233 | 2,930 | 6,502 | 4,071 |
30 Sep 17 | 19,738 | 2,722 | 6,387 | 4,071 |
30 Jun 17 | 18,670 | 2,079 | 6,095 | 4,071 |
31 Mar 17 | 18,085 | 1,863 | 5,920 | 4,071 |
31 Dec 16 | 17,483 | 1,668 | 6,061 | 3,348 |
30 Sep 16 | 17,190 | 1,751 | 5,511 | 3,348 |
30 Jun 16 | 17,091 | 1,620 | 5,618 | 3,348 |
31 Mar 16 | 17,438 | 1,789 | 5,478 | 3,348 |
31 Dec 15 | 17,594 | 2,299 | 5,383 | 3,334 |
30 Sep 15 | 17,482 | 2,281 | 5,405 | 3,334 |
30 Jun 15 | 17,192 | 1,861 | 5,678 | 3,334 |
31 Mar 15 | 16,855 | 1,682 | 5,713 | 3,334 |
31 Dec 14 | 16,380 | 1,066 | 6,792 | 2,202 |
30 Sep 14 | 16,516 | 1,319 | 6,895 | 2,202 |
30 Jun 14 | 16,117 | 1,316 | 6,280 | 2,202 |
31 Mar 14 | 15,705 | 1,296 | 6,116 | 2,202 |
31 Dec 13 | 15,669 | 1,517 | 6,269 | 1,991 |
質の高い収益: 4552 is currently unprofitable.
利益率の向上: 4552 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 4552 is unprofitable, and losses have increased over the past 5 years at a rate of 0.3% per year.
成長の加速: Unable to compare 4552's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: 4552 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (38.7%).
株主資本利益率
高いROE: 4552 has a negative Return on Equity (-0.71%), as it is currently unprofitable.